Corrigendum to ’ Phase 1 clinical trial on Orgasmic Meditation (OM): Assessing safety and feasibility as a meditation practice for individuals with PTSD’[Contemporary Clinical Trials Communications 45 (2025) 101451]
Contemporary Clinical Trials Communications · 2026-11 · 101709
DOI: 10.1016/j.conctc.2026.101709 ↗Kurz gefasst
Fachartikel in der Zeitschrift Contemporary Clinical Trials Communications, 2026-11. Verfasst von Daniel Kriegman und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Kriegman, D., Pelletier, R., Griggs, C., & Roth, C. (2026). Corrigendum to ’ Phase 1 clinical trial on Orgasmic Meditation (OM): Assessing safety and feasibility as a meditation practice for individuals with PTSD’[Contemporary Clinical Trials Communications 45 (2025) 101451]. Contemporary Clinical Trials Communications, 101709. https://doi.org/10.1016/j.conctc.2026.101709
Vancouver
Kriegman D, Pelletier R, Griggs C, Roth C. Corrigendum to ’ Phase 1 clinical trial on Orgasmic Meditation (OM): Assessing safety and feasibility as a meditation practice for individuals with PTSD’[Contemporary Clinical Trials Communications 45 (2025) 101451]. Contemporary Clinical Trials Communications. 2026:101709. doi:10.1016/j.conctc.2026.101709
BibTeX
@article{Kriegman2026,
author = {Kriegman, Daniel and Pelletier, Rachel and Griggs, Caroline and Roth, Caryn},
title = {Corrigendum to ’ Phase 1 clinical trial on Orgasmic Meditation (OM): Assessing safety and feasibility as a meditation practice for individuals with PTSD’[Contemporary Clinical Trials Communications 45 (2025) 101451]},
journal = {Contemporary Clinical Trials Communications},
year = {2026},
pages = {101709},
doi = {10.1016/j.conctc.2026.101709}
}
EUVIMED